Biologics and JAK inhibitors for atopic manifestations in inborn errors of immunity: a systematic review
Atopy might be the initial or dominant manifestation in patients with inborn errors of immunity (IEIs). Biologics and Janus kinase (JAK) inhibitors have emerged as targeted options for atopic disorders in IEIs refractory to conventional treatment. We conducted a systematic review of PubMed, Web of Science, a...